Add-on Rehmannia-6–Based Chinese Medicine in Type 2 Diabetes and CKD

医学 蛋白尿 糖尿病 2型糖尿病 肾功能 置信区间 内科学 肾脏疾病 随机对照试验 肌酐 中医药 随机化 临床终点 人口 相伴的 泌尿科 内分泌学 替代医学 病理 环境卫生
作者
Kam Wa Chan,Alfred Siu Kei Kwong,Kathryn Choon Beng Tan,Sing Leung Lui,Gary Chi-wang Chan,Tai‐Pang Ip,Wai Han Yiu,Benjamin J. Cowling,Vivian Taam Wong,Lixing Lao,Yibin Feng,Kar Neng Lai,Sydney Tang
出处
期刊:Clinical Journal of The American Society of Nephrology [Lippincott Williams & Wilkins]
卷期号:18 (9): 1163-1174 被引量:11
标识
DOI:10.2215/cjn.0000000000000199
摘要

BACKGROUND: Diabetes is the leading cause of CKD and kidney failure. We assessed the real-world effectiveness of Rehmannia-6-based Chinese medicine treatment, the most used Chinese medicine formulation, on the change in eGFR and albuminuria in patients with diabetes and CKD with severely increased albuminuria. METHODS: In this randomized, assessor-blind, standard care-controlled, parallel, multicenter trial, 148 adult patients from outpatient clinics with type 2 diabetes, an eGFR of 30-90 ml/min per 1.73 m 2 , and a urine albumin-to-creatinine ratio (UACR) of 300-5000 mg/g were randomized 1:1 to a 48-week add-on protocolized Chinese medicine treatment program (using Rehmannia-6-based formulations in the granule form taken orally) or standard care alone. Primary outcomes were the slope of change in eGFR and UACR between baseline and end point (48 weeks after randomization) in the intention-to-treat population. Secondary outcomes included safety and the change in biochemistry, biomarkers, and concomitant drug use. RESULTS: The mean age, eGFR, and UACR were 65 years, 56.7 ml/min per 1.73 m 2 , and 753 mg/g, respectively. Ninety-five percent ( n =141) of end point primary outcome measures were retrievable. For eGFR, the estimated slope of change was -2.0 (95% confidence interval [CI], -0.1 to -3.9) and -4.7 (95% CI, -2.9 to -6.5) ml/min per 1.73 m 2 in participants treated with add-on Chinese medicine or standard care alone, resulting in a 2.7 ml/min per 1.73 m 2 per year (95% CI, 0.1 to 5.3; P = 0.04) less decline with Chinese medicine. For UACR, the estimated proportion in the slope of change was 0.88 (95% CI, 0.75 to 1.02) and 0.99 (95% CI, 0.85 to 1.14) in participants treated with add-on Chinese medicine or standard care alone, respectively. The intergroup proportional difference (0.89, 11% slower increment in add-on Chinese medicine, 95% CI, 0.72 to 1.10; P = 0.28) did not reach statistical significance. Eighty-five adverse events were recorded from 50 participants (add-on Chinese medicine versus control: 22 [31%] versus 28 [36%]). CONCLUSIONS: Rehmannia-6-based Chinese medicine treatment stabilized eGFR on top of standard care alone after 48 weeks in patients with type 2 diabetes, stage 2-3 CKD, and severely increased albuminuria. CLINICAL TRIAL REGISTRY: Semi-individualized Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy (SCHEMATIC), NCT02488252 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
weiwei完成签到,获得积分10
1秒前
传奇3的应助被ty12390采纳,获得10
1秒前
传奇3的应助被微风采纳,获得10
2秒前
董子瑜发布了新的文献求助10
2秒前
kobe发布了新的文献求助10
2秒前
白白发布了新的文献求助10
2秒前
xier完成签到,获得积分10
2秒前
3秒前
hiittjw完成签到,获得积分10
3秒前
3秒前
阿金发布了新的文献求助10
4秒前
清城完成签到,获得积分10
4秒前
KD357完成签到,获得积分10
5秒前
今后的应助被老实的硬币采纳,获得10
5秒前
共享精神的应助被Ava采纳,获得10
5秒前
H2发布了新的文献求助10
6秒前
123456完成签到,获得积分10
7秒前
7秒前
RXE关注了科研通微信公众号
8秒前
科研通AI6.2的应助被fortuna采纳,获得10
8秒前
ww完成签到,获得积分10
8秒前
Meng发布了新的文献求助10
8秒前
9秒前
10秒前
SHY完成签到,获得积分20
10秒前
椰汁味完成签到,获得积分10
11秒前
哭泣煎蛋完成签到 ,获得积分10
11秒前
刘柳发布了新的文献求助10
11秒前
脑洞疼的应助被xh采纳,获得10
11秒前
烟花的应助被tph采纳,获得10
11秒前
12秒前
华仔的应助被zero采纳,获得10
12秒前
李健的小迷弟的应助被cc采纳,获得10
12秒前
啊啊发布了新的文献求助80
12秒前
ding的应助被蓝色记忆采纳,获得10
12秒前
sunnymoon发布了新的文献求助10
12秒前
隶书发布了新的文献求助60
13秒前
阿金完成签到,获得积分20
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161554
求助须知:如何正确求助?哪些是违规求助? 9556174
关于积分的说明 21732775
捐赠科研通 7751537
什么是DOI,文献DOI怎么找? 3427556
关于科研通互助平台的介绍 2552588
邀请新用户注册赠送积分活动 2472023